A small portable cold plasma device for the treatment of chronic and acute woun...
A small portable cold plasma device for the treatment of chronic and acute wounds.
terraplasma GmbH has developed a small, portable and battery-operated device – plasma care – for the treatment of chronic and acute wounds. Besides ensuring a sufficient supply of oxygen, avoiding an infection is the most importan...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
ChroWoDoc
Mobile Primary Care Device for Documentation and Analysis of...
75K€
Cerrado
BIOCURE
Novel Biomaterial for Improved and Cost efficient Wound Heal...
2M€
Cerrado
PID2020-112737RB-I00
DISEÑO DE UN SISTEMA AVANZADO MULTIFUNCIONAL PARA LA LIBERAC...
110K€
Cerrado
BIOCURE
Novel Biomaterial for Improved and Cost efficient Wound Heal...
71K€
Cerrado
ClearPlasma
ClearPlasma is an innovative medical device that enhances co...
71K€
Cerrado
Información proyecto plasmaCare
Duración del proyecto: 4 meses
Fecha Inicio: 2018-06-20
Fecha Fin: 2018-10-31
Líder del proyecto
TERRAPLASMA GMBH
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
71K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
terraplasma GmbH has developed a small, portable and battery-operated device – plasma care – for the treatment of chronic and acute wounds. Besides ensuring a sufficient supply of oxygen, avoiding an infection is the most important criterion to enable fast and uncomplicated wound healing. Hard-to-heal wounds have a negative impact on patient wellbeing, are challenging for clinicians to manage and are costly to the health economy. plasmaCare incorporates its innovative cold plasma technology where plasma care will allow for a disruptive wound therapy that can save healthcare costs by facilitating early discharge from hospital, reducing wound dressing frequency (e.g. nursing time) and promote faster healing processes.
terraplasma’s ambition is to reach the European market in 2020 with the innovation project boosting their efforts to fulfil this strategy: results of clinical studies on plasmaCare and their dissemination through the European network of skin specialists will be crucial to gain traction among patients, and healthcare providers in order to achieve the new product acceptance among customers and ultimately, their trust.
Incorporated in Germany in 2011 and maintaining its core business in Europe with an annual balance sheet of ~ €1M and a staff headcount of 9, the company has evolved along the years from a pure R&D start-up into a commercial enterprise. The proposed work in Phase 1 of the SME instrument fits into the overall terraplasma plan to reach market by contributing the financial resources needed to plan a fast, sound and wider deployment of the plasmaCare solution and the market uptake. It will also allow the SME to accomplish key feasibility activities and reduce the business risks, such as business planning, customer identification and outreach, and stronger IP management strategy.